In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy

Keyphrases

• Chemotherapy 100%
• Ovarian Cancer 100%
• In Situ 100%
• Tumor Microenvironment 100%
• Neoadjuvant Chemotherapy 100%
• Metabolic Alterations 100%
• Poor Response 100%
• Tumor 60%
• Post-neoadjuvant 60%
• High-grade Serous Ovarian Cancer (HGSOC) 40%
• Response to Chemotherapy 40%
• Excellent Response 40%
• Clinical Response 20%
• Phosphoproteomics 20%
• Metabolism 20%
• Predictive Models 20%
• Tumor Response 20%
• Response to Neoadjuvant Chemotherapy 20%
• Neoadjuvant 20%
• Hypoxia-inducible factor-1α (HIF-1α) 20%
• Patient Tumor 20%
• MS-based Proteomics 20%
• Differential Abundance 20%
• Oxygen Dependence 20%
• Differential Response 20%
• Ovarian Tissue 20%
• 10-fold Cross Validation 20%
• Ridge Regression Model 20%
• Tyrosine Metabolism 20%
• Proline Hydroxylation 20%
• Urea Cycle 20%
• Pyrimidine Biosynthesis 20%
• Actionable Target 20%
• Triage Algorithm 20%
• Quantitative MS 20%
• Aspartate Metabolism 20%
• Nucleotide Biosynthesis 20%
• Phenylalanine Metabolism 20%
• Asparagine Metabolism 20%
• DESI-MSI 20%

Biochemistry, Genetics and Molecular Biology

• Metabolic Pathway 100%
• Metabolite 100%
• Tyrosine 33%
• Phosphoproteomics 33%
• Electrospray Mass Spectrometry 33%
• Asparagine 33%
• Hypoxia-Inducible Factors 33%
• Urea Cycle 33%
• Nucleotide Metabolism 33%
• Hydroxylation 33%
• Pyrimidine Metabolism 33%
• Desorption Electrospray Ionization 33%
• Aspartic Acid 33%
• Proline 33%
• Phenylalanine 33%
• Proteomics 33%

Immunology and Microbiology

• Metabolite 100%
• Electrospray Mass Spectrometry 33%
• Hypoxia Inducible Factor 33%
• Cancer Tissue 33%
• Nucleotide Metabolism 33%
• Hydroxylation 33%
• Desorption 33%
• Urea Cycle 33%
• Pyrimidine Metabolism 33%
• Proteomics 33%
• Tyrosine 33%
• Phenylalanine 33%
• Asparagine 33%
• Proline 33%